| Clinical data | |
|---|---|
| Other names | AMAP102 |
| Routes of administration | Oral1 |
| Drug class | Serotonin 5-HT2B receptor antagonist; Serotonin 5-HT2C receptor antagonist |
AMAP-102 is a serotonin 5-HT2B and 5-HT2C receptor antagonist which is or was under development for the treatment of musculoskeletal pain and rheumatoid arthritis.123 It is taken by mouth.1
The drug is or was under development by AnaMar AB.123 A phase 1 clinical trial was completed in 2009 and the results of a phase 2 trial were reported in 2014.1 It failed to reduce inflammatory pain in people with osteoarthritis in this trial and its development was said to have been discontinued.1 However, the drug is still listed as being in active development as of January 2025.23 The chemical structure of AMAP-102 does not appear to have been disclosed.123
References
References
- Wang Q, Zhou Y, Huang J, Huang N (January 2021). "Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor". Pharmaceuticals (Basel). 14 (2): 76. doi:10.3390/ph14020076. PMC 7909583. PMID 33498477.
- "AMAP 102". AdisInsight. 4 November 2017. Retrieved 14 January 2025.
- "Delving into the Latest Updates on AMAP-102 with Synapse". Synapse. 21 November 2024. Retrieved 14 January 2025.